NCT06441045

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in NSCLC Patients With Leptomeningeal Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI: a Phase II Randomized, Multicenter Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 112 (estimated)
• Sponsor: Fujian Cancer Hospital · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

We aim to compare the efficacy and safety of double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus double Dose of Third-generation EGFR-TKI in patients with leptomeningeal progression following the treatment of routine dose of EGFR-TKI,

Conditions

• Leptomeningeal Metastasis

Interventions

Type	Name	Description
DRUG	Double Dose of Third-generation EGFR-TKI	Double Dose of Third-generation EGFR-TKI
DRUG	Intrathecal Pemetrexed	Intrathecal Pemetrexed

Timeline

• Start date: 2024-10-01
• Primary completion: 2028-04-01
• Completion: 2028-10-01
• First posted: 2024-06-04
• Last updated: 2024-06-04

Locations

1 site across 1 country: China